静脉用丙种球蛋白辅助治疗儿童重症腺病毒肺炎的回顾性分析

临床儿科杂志 ›› 2014, Vol. 32 ›› Issue (5): 449-452.

静脉用丙种球蛋白辅助治疗儿童重症腺病毒肺炎的回顾性分析

蒲开彬，黄英，舒畅，闫莉，韩环立

重庆医科大学附属儿童医院呼吸中心儿童发育疾病研究教育部重点实验室（重庆 400014）

收稿日期:2013-11-15 出版日期:2014-05-15 发布日期:2014-05-15

Intravenous immunoglobulin in the treatment of severe adenovirus pneumonia in children：A clinical observation of 210 cases　

PU Kaibin, HUANG Ying, SHU Chang, YAN Li, HAN Huanli.

(Department of Respiratory Center，the Children’s Hospital of Chongqing Medical University, Chongqing 400014, China)

Received:2013-11-15 Online:2014-05-15 Published:2014-05-15

摘要/Abstract

摘要：

　目的　观察静脉用丙种球蛋白（IVIG）治疗儿童重症腺病毒肺炎（SAP）的临床疗效和并发症。方法　回顾性分析2009年6月至2011年6月210例住院SAP患儿的临床资料，根据是否曾应用IVIG治疗分为IVIG组（109例）和对照组（101例），比较两组的疗效、持续发热时间、住院时间、机械通气时间及并发症比例等。结果　两组患儿在入院时病情严重程度及基础疾病比例差异无统计学意义（P均>0.05）；均给予抗病毒、抗细菌等综合对症支持治疗；IVIG组应用IVIG 250~400 mg/(kg·d)，持续3~5 d。IVIG组平均持续发热时间及住院时间，以及部分患者机械通气时间均比对照组缩短；并发胸腔积液、肺不张、心肌炎、中毒性脑病的比例较对照组减少；有效率高于对照组，差异均有统计学意义（P均<0.05）。IVIG组患儿在应用IVIG过程中未出现明显不良反应。结论　IVIG辅助治疗儿童SAP有效且安全。

Abstract: 　Objective　To observe the clinical effect and complications of intravenous immunoglobulin（IVIG）in the treatment of severe adenovirus pneumonia（SAP） in children. Methods Clinical data of 210 hospitalized children with SAP from June 2009 to June 2011were retrospectively analyzed.Patientswere divided into IVIG group (109 cases) and control group (101 cases) tocompare the therapeutic effects, duration of fever,length of stay in hospital,duration of mechanical ventilation, and complications between the two groups. Results There was no difference in the severity of illness on admission and underlying diseases between the two groups. Both groups were givenantiviral,antibacterialandcomprehensivesupportingtherapy, andin theIVIG groupIVIG(250-400mg/(kg.d)were administeredfor 3-5d. The mean hospital stay and fever time of the IVIG group were significantly shortened comparing to that of the control group, and the time of mechanical ventilation on the IVIG groupis less than that of the Non-IVIG group.Incidence rate of pleural effusion ,atelectasis,myocarditis and toxic encephalopathy in the IVIG group is lower than the control group,and the cure rateand effective therapy of the IVIG groupis higher than control group,all of the difference was statistically significant(P<0.05). No adverse drug reaction was observed. Conclusions IVIG is safe and effective in the treatment of SAP in children.

蒲开彬，黄英，舒畅，闫莉，韩环立. 静脉用丙种球蛋白辅助治疗儿童重症腺病毒肺炎的回顾性分析[J]. 临床儿科杂志, 2014, 32(5): 449-452.

PU Kaibin,HUANG Ying,SHU Chang,YAN Li,HAN Huanli.. Intravenous immunoglobulin in the treatment of severe adenovirus pneumonia in children：A clinical observation of 210 cases　[J]. , 2014, 32(5): 449-452.

参考文献

[1] 胡亚美，江载芳. 诸福棠实用儿科学 [M]. 7版. 北京：人民卫生出版社，2003:1191-1195.
[2] Lu MP, Ma LY, Zheng Q, et al. Clinical characteristics of adenovirus associated lower respiratory tract infection in children [J]. World J Pediatr, 2013, 9(4):346-349.
[3] 刘秀云，江载芳. 腺病毒肺炎12例临床特点和鉴别诊断分析 [J]. 临床儿科杂志，2007, 25（6）：454-456.
[4] British Thoracic Society of Standards of Care Committee. BTS guidelines for the community acquired pneumonia in childhood [J]. Thorax, 2002, 57(Supp1): S1-S24.
[5] Ou ZY，Zeng QY，Wang FH，et al. Retrospective study of adenovirus in autopsied pulmonary tissue of pediatric fatal pneumonia in South China [J]. BMC Infect Dis, 2008,8:122.
[6] Chuang YY，Chiu CH，Wong KS，et a1. Severe adenovirus infection in children [J]. J Microbiol Immunol Infect，2003，36(1): 37-40.
[7] 刘秀云，江载芳. 腺病毒肺炎后遗症的再认识 [J]. 临床儿科杂志.2009, 27(1): 91-93.
[8] Low SY, Tan TT, Lee CH, et al. Severe adenovirus pneumonia requiring extracorporeal membrane oxygenation support - Serotype 7 revisited [J]. Respir Med, 2013, 107(11):1810-1813.
[9] 尹成军，薛国昌. 大剂量丙种球蛋白对腺病毒肺炎患儿免疫功能的影响 [J]. 中国医师进修杂志，2006, 9(6): 28-29.
[10] 韩子明. 静脉注射丙种球蛋白在儿童感染性疾病中的作用 [J]. 实用儿科临床杂志, 2009, 24(9): 646-648.
[11] Drucker NA1, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population [J]. Circulation, 1994, 89(1):252-257.
[12] Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives [J]. Heart Fail Rev, 2013,18(6):761-795.
[13] Hughes RA, Dalakas MC, Cornblath DR, et al. Clinical applications of intravenous immunoglobulins in neurology [J]. Clin Exp Immunol, 2009, 158(Suppl 1):34-42.
[14] Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook [J]. Clin Exp Immunol, 2009, 158(Suppl 1):51-59.
[15] Iwanaga N, Nakamura S, Tanaka A, et al. An adult case of influenza-associated encephalitis successfully treated with high dose intravenous immunoglobulins [J]. Kansenshogaku Zasshi, 2012, 86(3): 295-299.
[16] Kitanovski L, Kopriva S, Pokorn M, et al. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG [J]. J Pediatr Hematol Oncol, 2013, 35(7):e311-e313.
[17] 林贞,邱彬玮. 丙种球蛋白治疗小儿重症肺炎68例临床观察 [J]. 中国临床医师, 2010, 38(5):46-47.
[18] 钟礼立, 梁沫, 谢乐云, 等. 腺病毒肺炎12例临床分析 [J]. 临床儿科杂志, 2011, 29(8): 724-727.